Adrian Woolfson, BM, BCh, PhD, has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Dr. Woolfson previously worked at Pfizer Inc. and Bristol-Myers Squibb. Dr. Woolfson completed post-graduate training in internal medicine at Addenbrooke’s Hospital Cambridge. He holds a BM BCh degree in Clinical Medicine from Oxford University and a PhD in molecular immunology from Cambridge University.